Methotrexate in patients with primary biliary cirrhosis who respond incompletely to treatment with ursodeoxycholic acid

Digestive Diseases and Sciences

Volumn 55, Issue 11, 2010, Pages 3207-3217

  Kaplan, Marshall M ^a   Bonder, Alan ^a   Ruthazer, Robin ^a   Bonis, Peter A L ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

Colchicine; Primary biliary cirrhosis; Response to methotrexate; Unresponsive to ursodiol

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; COLCHICINE; FOLINIC ACID; LIVER ENZYME; METHOTREXATE; PREDNISONE; URSODEOXYCHOLIC ACID;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; APHTHOUS ULCER; ARTICLE; CONTROLLED STUDY; HEPATITIS; HUMAN; HUMAN TISSUE; INTERSTITIAL PNEUMONIA; LEAN BODY WEIGHT; LIVER BIOPSY; LIVER DISEASE; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; TREATMENT RESPONSE;

ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASES; BILIRUBIN; CHOLAGOGUES AND CHOLERETICS; COLCHICINE; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FIBROSIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER; LIVER CIRRHOSIS, BILIARY; LIVER FUNCTION TESTS; METHOTREXATE; TREATMENT FAILURE; URSODEOXYCHOLIC ACID;

EID: 78149361818     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-010-1291-5     Document Type: Article

References (31)

1. K Lindor M Gershwin R Poupon M Kaplan N Bergasa E Heathcote 2009 AASLD practice guidelines: primary Biliary Cirrhosis Hepatology 50 291 308 10.1002/hep.22906 19554543
2. Y Gong Z Huang E Christensen C Gluud 2007 Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systemic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analysis Am J Gastroenterol 102 1799 1807 1:CAS:528: DC%2BD2sXhtVemsLrP 10.1111/j.1572-0241.2007.01235.x 17459023 (Pubitemid 47206681)
3. A Parés L Caballería J Rodés 2006 Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid Gastroenterology 130 715 720 10.1053/j.gastro.2005.12.029 16530513 (Pubitemid 43374522)
4. Corpechot C, Abenavoli L, Rabahi N, Chrétien Y, Andréani T, Johanet C, Chazouillères O, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology. 2008;48:871-877.
5. J Lee A Belanger S Friedman N Bach 2006 Transplantation trends among primary biliary cirrhosis patients from 1995 to 2004 Hepatology 44 628A
6. M Kaplan R Poupon 2009 Treatment with immunosupressives in patients with primary biliary cirrhosis who fail to respond to ursodiol Hepatology 50 562 10.1002/hep.22831
7. MM Kaplan TA Knox SA Arora 1988 Primary biliary cirrhosis treated with low-dose oral pulse methotrexate Ann Intern Med 109 429 431 1:STN:280: DyaL1czgvVWhsA%3D%3D 3408057
8. M Kaplan R DeLellis H Wolfe 1997 Sustained biochemical and histological remission of primary biliary cirrhosis in response to medical treatment Ann Intern Med 126 682 688 1:STN:280:DyaK2s3mslCktQ%3D%3D 9139553
9. PA Bonis MM Kaplan 1997 The effects of colchicine and methotrexate are additive to ursodeoxycholic acid for patients with primary biliary cirrhosis (PBC) who have responded incompletely to ursodeoxycholic acid Hepatology 26 438A 10.1002/hep.510260436
10. B Combes SS Emerson NL Flye SJ Munoz VA Luketic MJ Mayo TM McCashland, et al. 2005 Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis Hepatology 42 1184 1193 1:CAS:528: DC%2BD2MXht1amtbvF 10.1002/hep.20897 16250039 (Pubitemid 43112686)
11. M Hendrickse E Rigney M Giaffer I Soomro D Triger J Underwood D Gleeson 1999 Low-dose methotrexate is ineffective in primary biliary cirrhosis: long-term results of a placebo-controlled trial Gastroenterology 117 400 407 1:CAS:528:DyaK1MXltFKqtrg%3D 10.1053/gast.1999.0029900400 10419922 (Pubitemid 29352949)
12. MM Kaplan S Cheng LL Price PA Bonis 2004 A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: ten-year results Hepatology 39 915 923 1:CAS:528:DC%2BD2cXjtlCqsrw%3D 10.1002/hep.20103 15057894 (Pubitemid 38428929)
13. Gong Y, Gluud C. Methotrexate for primary biliary cirrhosis. Cochrane Database Syst Rev. 2005;Jul 20;(3):CD004385, PMID: 16034929.
14. C Corpechot F Carrat R Poupon RE Poupon 2002 Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients Gastroenterology 122 652 658 1:CAS:528:DC%2BD38Xit1ejtrY%3D 10.1053/gast.2002.31880 11874998
15. K Lindor 2007 Ursodeoxycholic acid for the treatment of primary biliary cirrhosis N Engl J Med 357 1524 1529 1:CAS:528:DC%2BD2sXhtFKmurbN 10.1056/NEJMct074694 17928600 (Pubitemid 47572638)
16. MM Kaplan EM Gershwin 2005 Primary biliary cirrhosis N Eng J Med 353 1261 1273 1:CAS:528:DC%2BD2MXhtVeltLbI 10.1056/NEJMra043898 (Pubitemid 41345948)
17. ZD Goodman PR McNally DR Davis KG Ishak 1995 Autoimmune cholangitis: a variant of primary biliary cirrhosis Dig Dis Sci 40 1232 1242 1:STN:280:DyaK2MzgtVKisw%3D%3D 10.1007/BF02065530 7781439
18. R Poupon O Chazouilleres C Corpechot Y Chretien 2006 Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis Hepatology 44 85 90 10.1002/hep.21229 16799997 (Pubitemid 44049141)
19. M Kaplan C Schmid A McKusick D Provenzale A Sharma T Sepe 1993 Double-blind trial of methotrexate (MTX) versus colchicine (COLCH) in primary biliary cirrhosis Hepatology 18 176A
20. O Chazouilleres D Wendum L Serfaty S Montembault O Rosmorduc R Poupon 1998 Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome; clinical features and response to therapy Hepatology 28 296 301 1:CAS:528: DyaK1cXlsFGgu7c%3D 10.1002/hep.510280203 9695990 (Pubitemid 28363652)
21. K Novak MG Swain 2008 Role of methotrexate in the treatment of chronic cholestatic disorders Clin Liver Dis 12 81 96 10.1016/j.cld.2007.11.011 18242498 (viii) (Pubitemid 351175656)
22. C Corpechot L Abenavoli N Rabahi Y Chretien T Andreani C Johanet O Chazouilleres, et al. 2008 Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis Hepatology 48 871 877 1:CAS:528:DC%2BD1cXhtFKrsLfN 10.1002/hep.22428 18752324
23. MA Babatin FM Sanai MG Swain 2006 Methotrexate therapy for the symptomatic treatment of primary biliary cirrhosis patients, who are biochemical incomplete responders to ursodeoxycholic acid therapy Aliment Pharmacol Ther 24 813 820 1:CAS:528:DC%2BD28XhtFGqsrjO 10.1111/j.1365-2036.2006.03048.x 16918885
24. PAL Bonis M Kaplan 1999 Methotrexate in primary biliary cirrhosis unresponsive to ursodeoxycholic acid: an observational study in 10 patients Gastroenterology 117 395 399 1:CAS:528:DyaK1MXltFKqtrs%3D 10.1053/gast.1999. 0029900395 10419921 (Pubitemid 29352948)
25. PA Bonis M Kaplan 2006 Methotrexate for treatment of primary biliary cirrhosis Hepatology 43 632 10.1002/hep.21058 16496314 (author reply 632-633)
26. A Nyfors 1977 Liver biopsies from psoriatics related to methotrexate therapy 3. Findings in post-methotrexate liver biopsies from 160 psoriatics Acta Pathol Microbiol Scand A 85 511 518 1:STN:280:DyaE2s3mtlWnsw%3D%3D 899789 (Pubitemid 8149758)
27. HJ Roenigk R Auerbach H Maibach G Weinstein 1982 Methotrexate guidelines-revised J Am Acad Dermatol 6 145 155 10.1016/S0190-9622(82)80064-9 7037877
28. H Zachariae K Kragballe H Søgaard 1980 Methotrexate induced liver cirrhosis. Studies including serial liver biopsies during continued treatment Br J Dermatol 102 407 412 1:STN:280:DyaL3c3itV2jtw%3D%3D 10.1111/j.1365-2133.1980. tb06553.x 7387883
29. Y Yazici D Erkan M Harrison N Nikolov SA Paget 2005 Methotrexate use in rheumatoid arthritis is associated with few clinically significant liver function test abnormalities Clin Exp Rheumatol 23 517 520 1:STN:280: DC%2BD2MvivFShtw%3D%3D 16095122
30. A Menter N Korman C Elmets S Feldman JM Gelfand KB Gordon, et al. 2009 Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents J Am Acad Dermatol 61 451 485 1:CAS:528: DC%2BD1MXhtFOitrzE 10.1016/j.jaad.2009.03.027 19493586
31. K Saag GG Teng NM Patkar J Anuntiyo C Finney J Curtis, et al. 2008 American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis Arthritis Rheum 15 762 784 10.1002/art.23721 (Pubitemid 351847559)